167 related articles for article (PubMed ID: 20846389)
1. Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma.
Dun X; Jiang H; Zou J; Shi J; Zhou L; Zhu R; Hou J
Mol Cancer; 2010 Sep; 9():247. PubMed ID: 20846389
[TBL] [Abstract][Full Text] [Related]
2. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
3. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
Levasseur R; Lacombe D; de Vernejoul MC
Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
[TBL] [Abstract][Full Text] [Related]
4. Structural insight into the mechanisms of Wnt signaling antagonism by Dkk.
Chen L; Wang K; Shao Y; Huang J; Li X; Shan J; Wu D; Zheng JJ
J Biol Chem; 2008 Aug; 283(34):23364-70. PubMed ID: 18524778
[TBL] [Abstract][Full Text] [Related]
5. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
6. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma.
Zhang ZC; Liu JX; Shao ZW; Pu FF; Wang BC; Wu Q; Zhang YK; Zeng XL; Guo XD; Yang SH; He TC
Medicine (Baltimore); 2017 Jul; 96(27):e7245. PubMed ID: 28682874
[TBL] [Abstract][Full Text] [Related]
8. Wnt signaling in B-cell neoplasia.
Qiang YW; Endo Y; Rubin JS; Rudikoff S
Oncogene; 2003 Mar; 22(10):1536-45. PubMed ID: 12629517
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of disease-associated polymorphism LRP5.Q89R.
Mao W; Wordinger RJ; Clark AF
Mol Vis; 2011 Apr; 17():894-902. PubMed ID: 21528003
[TBL] [Abstract][Full Text] [Related]
10. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
[TBL] [Abstract][Full Text] [Related]
11. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
[TBL] [Abstract][Full Text] [Related]
12. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.
Semënov MV; Tamai K; Brott BK; Kühl M; Sokol S; He X
Curr Biol; 2001 Jun; 11(12):951-61. PubMed ID: 11448771
[TBL] [Abstract][Full Text] [Related]
13. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization.
Chen Y; Hu Y; Lu K; Flannery JG; Ma JX
J Biol Chem; 2007 Nov; 282(47):34420-8. PubMed ID: 17890782
[TBL] [Abstract][Full Text] [Related]
14. Kremen1 restricts Dkk activity during posterior lateral line development in zebrafish.
McGraw HF; Culbertson MD; Nechiporuk AV
Development; 2014 Aug; 141(16):3212-21. PubMed ID: 25038040
[TBL] [Abstract][Full Text] [Related]
15. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis.
Cheng JH; She H; Han YP; Wang J; Xiong S; Asahina K; Tsukamoto H
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G39-49. PubMed ID: 18006602
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
17. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.
Qiang YW; Chen Y; Brown N; Hu B; Epstein J; Barlogie B; Shaughnessy JD
Br J Haematol; 2010 Mar; 148(5):726-38. PubMed ID: 19961481
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional analysis of Dickkopf 4 (Dkk4): New insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins.
Patel S; Barkell AM; Gupta D; Strong SL; Bruton S; Muskett FW; Addis PW; Renshaw PS; Slocombe PM; Doyle C; Clargo A; Taylor RJ; Prosser CE; Henry AJ; Robinson MK; Waters LC; Holdsworth G; Carr MD
J Biol Chem; 2018 Aug; 293(31):12149-12166. PubMed ID: 29925589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
